Article information
Full text is only aviable in PDF
Bibliography/Bibliografia
[1.]
A. Araújo, et al.
Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células.
Rev Port Pneumol, 14 (2008), pp. 803-827
[2.]
National Comprehensive Cancer Network. Practice Guidelines in Oncology – v.2.2009 Non-Small Cell Lung Cancer. Disponível em: http://www.nccn.org/professional/physician_gls/f_guidelines.asp. (consulta a 5 de Março de 2009 .
[3.]
National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal – June 2008. Disponível em: http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf.
[4.]
F.A. Shepherd, J. Pereira, T. Ciuleanu, et al.
Erlotinib in previously treated non-small cell lung cancer.
N Engl J Med, 353 (2005), pp. 123-132
[5.]
F.A. Shepherd, et al.
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy.
J Clin Oncol, 18 (2000), pp. 2095
[6.]
N. Hanna, F.A. Shepherd, F.V. Fossela, et al.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
J Clin Oncol, 22 (2004), pp. 1589-1597
[7.]
W. Kotowa, U. Gatzemeier, O. Pirk, et al.
A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Journal of Medical Economics, 10 (2007), pp. 255-271
[8.]
National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small-cell lung cancer, August 2007. Disponível em: http://www.nice.org.uk/TA124.
[9.]
M.A. Socinski, D.E. Morris, G.A. Masters, R. Lilenbaum.
Chemotherapeutic management of stage IV non-small cell lung cancer.
Chest, 123 (2003), pp. 226-243
[10.]
C. Gridelli, P. Maione, A. Rossi, et al.
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Expert Rev Anticancer Ther, 9 (2009), pp. 115-124
[11.]
T.E. Stinchcombe, M.A. Socinski.
Considerations for second-line therapy of non-small cell lung cancer.
Oncologist, 13 (2008), pp. 28-36
[12.]
J. Carlson, N. Oestreicher, D.P. Lubeck, et al.
Cost-effectiveness of erlotinib vs docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology, 25 (2007), pp. 425s
[13.]
C. Chouaid, A. Vergnenegre, A. Moser, et al.
Economic impact of second-and third-line erlotinib treatment of non small-cell lung cancer: a French observational study.
Value in Health, 10 (2007), pp. A322
[14.]
S. Capri, A. Morabito, G. Carillio, et al.
Economic evaluation of erlotinib, docetaxel and pemetrexed as seco nd line treatment in patients with advanced nonsmall-cell lung cancer (NSCLC): A cost-minimization in Italian hospitals.
Value in Health, 10 (2007), pp. A333
[15.]
S. Stefani, M.G. Saggia, E.A. Santos.
Cost-minimization analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small-cell lung cancer (NSCLC) from the perspective of a private payer in Brazil.
Value in Health, 10 (2007), pp. A332k
[16.]
T.C. Hsia, G.C. Chang, Y.M. Chen, et al.
Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan.
Value in Health, 10 (2007), pp. A325
[17.]
O. Batigun, E. Yildrim.
Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey. PCN77.
Value in Health, 10 (2007), pp. A234
Copyright © 2009. Sociedade Portuguesa de Pneumologia
